Sign up to save your podcasts
Or
Share Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma
Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.
View all episodes
By Dr. Neil Love
4.4
6969 ratings
Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.
More shows like Hematologic Oncology Update
View all
JAMA Editors' Summary
139 Listeners
Gastrointestinal Cancer Update
17 Listeners
Lung Cancer Update
32 Listeners
Prostate Cancer Update
14 Listeners
Breast Cancer Update
66 Listeners
Gynecologic Oncology Update
13 Listeners
Dermatologic Oncology Update
0 Listeners
NEJM This Week
320 Listeners
Research To Practice | Oncology Videos
111 Listeners
The Hematologist
27 Listeners
JAMA Clinical Reviews
501 Listeners
Annals On Call Podcast
195 Listeners
Blood Podcast
54 Listeners
Oncology Today with Dr Neil Love
60 Listeners
WolverHeme Happy Hour
29 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners